Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Beijing Luzhu Biotechnology Co's Pretax Margin % or its related term are showing as below:
HKSE:02480's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.895 * Ranked among companies with meaningful Pretax Margin % only.
Beijing Luzhu Biotechnology Co (HKSE:02480) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Beijing Luzhu Biotechnology Co Pretax Margin % Related Terms
Beijing Luzhu Biotechnology Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Luzhu Biotechnology Co Pretax Margin % Chart
HKSE:02480 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Beijing Luzhu Biotechnology Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Luzhu Biotechnology Co Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Luzhu Biotechnology Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Beijing Luzhu Biotechnology Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Luzhu Biotechnology Co (HKSE:02480) has a Pretax Margin % of % as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Beijing Luzhu Biotechnology Co and its competitors. According to the industry distribution chart, Beijing Luzhu Biotechnology Co ranks #999999 out of 942 companies in the Biotechnology industry.
Is Beijing Luzhu Biotechnology Co's Pretax Margin % too high?
Beijing Luzhu Biotechnology Co's current Pretax Margin % is %. Based on the distribution chart, Beijing Luzhu Biotechnology Co ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Beijing Luzhu Biotechnology Co has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Luzhu Biotechnology Co's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Luzhu Biotechnology Co ranks #999999 out of 942 companies for Pretax Margin %. This places Beijing Luzhu Biotechnology Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Beijing Luzhu Biotechnology Co and its competitors. Beijing Luzhu Biotechnology Co's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Luzhu Biotechnology Co stock overvalued right now?
Beijing Luzhu Biotechnology Co (HKSE:02480) has a current Pretax Margin % of %. The current Pretax Margin % is %. Beijing Luzhu Biotechnology Co's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Beijing Luzhu Biotechnology Co (HKSE:02480), the current Pretax Margin % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beijing Luzhu Biotechnology Co Business Description
Beijing Luzhu Biotechnology Co., Ltd. is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group's product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
24GF Score
Get the complete analysis for HKSE:02480
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02480 has been successfully added to your 
